Cardiac Marker Testing Market: Growth, Size, Share, and Trends

Market Growth Outlook Summary

The global cardiac marker testing market growth forecasted to transform from USD 4.4 billion in 2023 to USD 6.9 billion by 2028, driven by a CAGR of 9.4%. Increase in chronic heart conditions and aging population, increasing research & funding initiatives from organizations and worldwide rise in prevalence of cardiovascular diseases are a few drivers that collectively contribute to the growth of the cardiac marker testing industry, and as healthcare technologies continue to evolve, the demand for cardiac marker testing is expected to rise further in the upcoming years. However, challenges for regulatory issues, sampling collection and storage limits the market growth.

Attractive Opportunities in the Cardiac Marker Testing Market

To know about the assumptions considered for the study, Request for Free Sample Report

Cardiac Marker Testing Market: Market Dynamics

Driver: Increase in prevalence of cardiovascular diseases

The escalating prevalence of cardiovascular diseases stands as a significant driving force in the cardiac marker testing industry. This trend underscores a growing demand for advanced diagnostic solutions, compelling the healthcare industry to invest in innovative cardiac marker testing technologies. As heart-related conditions become more prevalent, the market is witnessing a surge in the adoption of these tests, emphasizing the critical need for accurate and efficient diagnostic tools. This demand, fueled by the rising incidence of cardiovascular diseases, is reshaping the landscape of cardiac marker testing and driving advancements in the sector.

Restraint: Issues related to storage and sampling collection

In epidemiological studies, cardiac biomarkers play a crucial role in investigating various stages of diseases in humans. This process necessitates meticulous handling and storage of valuable biological samples to extract extensive information from limited specimens. Maintaining stringent quality control is imperative to ensure the appropriate storage conditions, preventing data loss. The effectiveness of cardiac biomarker studies utilizing archived specimens heavily relies on the integrity of these samples and the methods employed in their processing, collection, and storage. Technical challenges in both sample collection and storage have the potential to impede the growth of the overall cardiac biomarkers market, particularly in the laboratory-based testing segment.

Opportunity: Emerging markets offering growth opportunities

Rapidly growing economies like India and China present substantial growth prospects in the field of cardiac diagnostics due to the expanding patient base caused by the rising prevalence of cardiovascular diseases in these nations. China has witnessed a significant surge in cardiovascular disease (CVD) due to heightened risk factors like high blood cholesterol, obesity, and diabetes mellitus. The escalating burden of cardiovascular diseases in these emerging economies is set to boost the demand for early disease diagnostics, thereby accelerating the adoption of cardiac marker testing products.

Cardiac Marker Testing Market Ecosystem

Major companies in this market include well-established and financially stable suppliers of cardiac marker testing. Prominent companies in this market include F. Hoffmann-La Roche AG (Switzerland), Abbott Laboratories (US), Danaher Corporation (US), Siemens Healthineers AG (Germany), PerkinElmer, Inc. (US), bioMérieux SA (France), Becton, Dickinson and Company (US), Bio-Rad Laboratories, Inc. (US), Thermo Fisher Scientific Inc. (US), among several others.

Reagents and kits segment of the cardiac marker testing industry to register significant growth rate over the forecast period of 2022-2028

Based on the product, the cardiac marker testing market is segmented into reagents and kits and instruments. Reagents and Kits segment to register a significant growth rate over the forecast period of 2022-2028. The expansion of the market for cardiac marker testing reagents and kits can be credited to the escalating volume of cardiac biomarker tests conducted, driven by the global prevalence of cardiovascular diseases (CVD) and the growing elderly demographic. This surge in demand for swift CVD diagnosis has led to the widespread adoption of rapid cardiac biomarker test kits. Furthermore, the market's growth is further bolstered by the introduction of new cardiac biomarker test kits by industry players.

Troponin I and T segment of the cardiac marker testing industry is the largest biomarker segment in 2022.

Cardiac troponin stands as the preferred biomarker for diagnosing acute myocardial infarction (AMI) due to its exceptional sensitivity and specificity. Recently, the cardiac marker testing market has witnessed the introduction of several high-sensitivity troponin assays, capable of detecting the protein swiftly and at significantly lower levels than standard troponin tests. Additionally, troponin biomarkers play a crucial role in identifying the risk of future heart events, even in asymptomatic individuals. These factors are expected to drive the growth of this segment in the forthcoming years.

Asia-Pacific region of the cardiac marker testing industry is expected to be the highest CAGR during the forecast period.

The cardiac marker testing market is divided into key regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. In 2022, North America held the largest market share in the global diagnostic imaging service market. However, the Asia Pacific region is anticipated to exhibit the highest Compound Annual Growth Rate (CAGR) during the forecast period. This growth is primarily attributed to the increasing incidence of cardiovascular diseases (CVD), a rise in testing procedures, improvements in healthcare infrastructure, and the widespread adoption of advanced immunoassay technology by clinical laboratories. Additionally, the market in the Asia Pacific region is set to receive a boost from the growing number of local manufacturers offering cardiac marker testing products and the increasing establishment of diagnostic laboratories in the area.

To know about the assumptions considered for the study, download the pdf brochure

As of 2022, prominent players in the market are F. Hoffmann-La Roche AG (Switzerland), Abbott Laboratories (US), Danaher Corporation (US), Siemens Healthineers AG (Germany), PerkinElmer, Inc. (US), bioMérieux SA (France), Becton, Dickinson and Company (US), Thermo Fisher Scientific Inc. (US), Bio-Rad Laboratories, Inc. (US), DiaSorin (Italy), and Tosoh Corporation (Japan), LSI Medience Corporation (Japan), Quidel Corporation (US), among others.

Scope of the Cardiac Marker Testing Industry:

This report has segmented the global cardiac marker testing market to forecast revenue and analyze trends in each of the following submarkets:

By Product Type

• Reagents and Kits
• Instruments
  • Chemiluminescence
  • Immunofluorescence
  • ELISA
  • Immunochromatography

By Biomarker Type

• Troponin I and T
• Creatine kinase-MB(CK-MB)
• Brain Natriuretic peptide (Bnp Or Nt-Probnp)
• Myoglobin
• High-sensitivity C-reactive protein(hs-CRP)
• Other Cardiac Biomarkers

By Diseases

• Myocardial Infarction
• Congestive Heart Failure
• Acute Coronary Syndrome
• Atherosclerosis
• Ischemia

By End User

• Laboratory Testing Facilities
  • Hospital Labs
  • Reference Labs
  • Contract Testing Labs
• Point-Of-Care Testing Facilities
• Academic Institutions

By Region

• North America
  • US
  • Canada
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
• MEA

Recent Developments of Cardiac Marker Testing Industry

• In 2023, BD announced that it had received FDA approval for its BD Vacutainer Troponin I Ultra test to be used in point-of-care settings which makes the BD Vacutainer Troponin I Ultra test the first and only FDA-approved point-of-care troponin test for the diagnosis of acute myocardial infarction (AMI).
• In 2023, Bio-Rad launched the Bio-Plex 2300 Troponin I Assay, a new high-sensitivity troponin I test that can detect cardiac damage earlier than other troponin tests..

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst